Social:

Facebook Instagram Linkedin
IPA

Philanthropy, Passion & Education International Perfusion Association The International Perfusion Association (IPA), a 501(c)(3) non-profit organization, is dedicated to enhancing education and supporting global cardiac surgery initiatives. Our mission is to amplify our philanthropic efforts by organizing cardiac surgery missions, assisting those engaged in similar endeavors, and bolstering local educational programs. We welcome individuals who are eager to make a meaningful difference in the world to join us in our cause. Make a Donation
Logo

Heart to Heart Mission

For more than 20 years, the IPA has performed life-saving heart surgery on over 400 patients in Santiago, Dominican Republic.

Read More
Logo

Ecuador Mission

The IPA is working with Harvard / MGH to expand their heart surgery mission program in Ecuador. We have a mission trip planned for October 2026. Stay tuned for more information.

Read More
Logo

Your Mission Trip

The IPA will gladly make donations to qualified charitable organizations who perform cardiac surgery mission work for patients in need.

Read More

700+ Patients

Help Mend a Heart!

Every member of our team is an unpaid volunteer, so please take comfort in knowing that 100% of all donated funds go directly to patient care. Your generosity is so very welcome and will help save lives!
Make a Donation

— Latest News —

Ranolazine and Cardioprotection During Myocardial Ischemia

Cardioprotective Effects of Ranolazine in Myocardial Infarction Mediated by Stimulation of the Endogenous Mediators Involved in Ischemic Preconditioning

This experimental rat-heart study tested whether ranolazine protects the myocardium through pathways similar to ischemic preconditioning. Using a Langendorff ischemia-reperfusion model, ranolazine reduced infarct size, LDH, CK-MB, troponin I, and improved ventricular function. These benefits were lost when nitric oxide, adenosine, bradykinin, or ATP-sensitive potassium channel pathways were blocked, supporting their role in ranolazine-mediated cardioprotection.

READ MORE
March 26, 2026
Bright Neonatal ECMO Team Managing Oxygen Targets

Impact of Early Hyperoxia on Outcomes During Neonatal and Pediatric Veno-Arterial Extracorporeal Life Support

This single-center retrospective cohort study examined 229 neonatal and pediatric VA-ECLS patients and found that early hyperoxia was common, affecting 79% of cases. Severe hyperoxia, defined as PaO2 above 300 mmHg, was linked to more cardiovascular or renal complications, but it was not independently associated with in-hospital mortality, acute kidney injury, or worse functional outcomes after adjustment. The authors support standardized oxygen targets during VA-ECLS.

READ MORE
March 26, 2026
OCEAN Trial Crossroads: M-TEER in Advanced Heart Failure

Outcomes of Transcatheter Edge-to-Edge Repair in Potentially Favorable Candidates for Left Ventricular Assist Device: Evidence From the OCEAN-Mitral Registry

This study evaluated mitral transcatheter edge-to-edge repair (M-TEER) in advanced heart failure patients who might otherwise have been reasonable candidates for left ventricular assist device (LVAD) therapy. Among 129 such patients from the OCEAN-Mitral Registry, procedural success was high at 96%, but long-term outcomes were less reassuring, especially in those with marked left ventricular enlargement. Larger LV size predicted cardiovascular death after M-TEER.

READ MORE
March 26, 2026
Global Bridge to Heart Transplant With Prolonged Impella 5.5 Support

Impact of Prolonged Impella 5.5 Support on Post-Transplant Outcomes: An Institutional Study

This institutional retrospective study evaluated 72 patients bridged to heart transplant with the Impella 5.5 and compared outcomes for support durations of 14 days or less versus more than 14 days. Prolonged support did not worsen 1-year survival, graft rejection, length of stay, or major complications. Although rehospitalization within a year was common, overall survival was excellent, supporting extended Impella 5.5 use as a safe bridge-to-transplant strategy.

READ MORE
March 26, 2026
Minimally Invasive Aortic Valve Replacement and Cardioplegia Strategy Comparison

Cardioplegia Strategies in Minimally Invasive Aortic Valve Replacement: An Inverse Probability of Treatment Weighting Analysis

This retrospective single-center study compared four cardioplegia strategies in 543 patients undergoing minimally invasive aortic valve replacement from 2010 to 2025. After inverse probability weighting balanced baseline differences, Calafiore and Custodiol were associated with less postoperative atrial fibrillation, lower CK/CK-MB release, and fewer respiratory complications than Buckberg, while mortality, stroke, ICU stay, hospital stay, and postoperative LVEF were similar.

READ MORE
March 25, 2026
Protecting Red Blood Cells During Liver Machine Perfusion

Reduction in Red Blood Cell Lysis by Polymer Intervention During Rodent Liver Normothermic Machine Perfusion

This preclinical rodent liver study tested whether Poloxamer 188 and Ficoll PM70 could reduce red blood cell hemolysis during normothermic machine perfusion. Both polymers lowered free hemoglobin and improved preservation of liver sinusoidal endothelial cells in donation after brain death and warm ischemia models. However, they did not significantly improve major perfusion metrics, and P188 showed a possible proinflammatory cytokine signal that warrants further study.

READ MORE
March 25, 2026
Load More
No more posts to show